Manufacturers Oppose Federal Price Controls for Drugs

The National Association of Manufacturers this week expressed its opposition to Congressional Democrats’ drug pricing bill (HR 3), which would allow the federal government to negotiate for decreased prices on behalf of Medicare.

The OMA echoes the warnings sounded in NAM’s letter to Speaker Nancy Pelosi (D-Cal.): “Price controls of any kind are never a correct solution.” PhRMA says HR 3 threatens access to medicines, future innovation, and U.S. jobs. 5/5/2021